A significant unmet medical need exists for the treatment of acute liver failure (ALF), given the lack of available effective interventions. A few artificial liver support systems have been developed to supplement liver function...
After taking more than a year to win over 1.17 per cent of the unitholders in the MFS-founded Premium Income Fund as part of its popular takeover bid, the business advised by the banned company director Jim Byrnes is now looking to list on the ASX.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.